PCRX -
Pacira BioSciences, Inc. Common Stock
Day |
1m |
10m |
60m |
PreMarket |
Market |
AfterHours |
Gap |
22.77 0.69 (3.03%) |
--- |
--- |
--- |
--- |
0.69 (3.03%) |
--- |
--- |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Earnings & Ratios
- Basic EPS:
- -0.11
- Diluted EPS:
- -0.11
- Basic P/E:
- -213.2727
- Diluted P/E:
- -213.2727
- RSI(14) 1m:
- 62.5
- VWAP:
- 23.47
- RVol:
- 0.6093
Events
Period |
Kind |
Movement |
Occurred At |
1m |
Price increase 1m |
23.24 +0.47 (+2.06%) |
Oct 15 09:30 |
Related News
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 03, 2025 12:00
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 05, 2025 12:00
Pacira BioSciences Debuts Inspiring New Film Highlighting One Patient’s Journey to Pain Relief and Innovation in Care at BIO 2025
Jun 18, 2025 12:00
Grabar Law Office Investigates Claims on Behalf of Shareholders of DoubleVerify Holdings, Inc. (NYSE: DV); NAPCO Securities Technologies, Inc. (NASDAQ: NSSC); Pacira Biosciences, Inc. (NASDAQ: PCRX); and Treace Medical Concepts, Inc. (NASDAQ: TMCI)
May 27, 2025 01:54
PCRX DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 14 Deadline in Securities Class Action – PCRX
Mar 14, 2025 00:04
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira
Mar 09, 2025 12:31
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 06, 2025 13:00
PACIRA BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX
Mar 06, 2025 03:28
PACIRA BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX
Mar 05, 2025 02:28
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira
Mar 03, 2025 18:44